articleTop 10% cited

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

Clinical Pharmacology & Therapeutics · 2005 · Vol. 78(4) · pp. 330–341

Eminy H.Y. Lee(National University Hospital)S RYAN(AstraZeneca (United States))Bruce K. Birmingham(National University Hospital)Julie Zalikowski(National University Hospital)Ruth March(AstraZeneca (United States))Helen Ambrose(AstraZeneca (United States))Raeanne C. Moore(Changi General Hospital)Caroline Lee(National University Hospital)Yu Chen(Changi General Hospital)Dennis W. Schneck✉(AstraZeneca (United States))

View via DOI Publisher page

Abstract

Plasma exposure to rosuvastatin and its metabolites was significantly higher in Chinese, Malay, and Asian-Indian subjects compared with white subjects living in the same environment.

Drug Transport and Resistance Mechanisms Pharmacogenetics and Drug Metabolism Liver Disease Diagnosis and TreatmentRosuvastatinSLCO1B1PharmacokineticsPharmacogeneticsRosuvastatin CalciumMedicinePharmacologyInternal medicineGenotypeChemistry

MeSH terms

Rosuvastatin CalciumAdultDietEnvironmentFemaleFluorobenzenesGene FrequencyGenotypeHalf-LifeHumansMaleProspective StudiesPyrimidinesSingaporeSulfonamides

Citations

476

FWCI

10.16

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines